CG
CPRX

Cynosure Group’s Catalyst Pharmaceutical CPRX Stock Holding History

Cynosure Group’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-18,777
Closed -$370K – 429
2025
Q3 		$370K Hold
18,777
– – 0.04% 309
2025
Q2 		$407K Buy
18,777
+3,408
+22% +$80.4K 0.05% 279
2025
Q1 		$373K Buy
15,369
+1,321
+9% +$29.7K 0.05% 186
2024
Q4 		$293K Sell
14,048
-3,688
-21% -$79.2K 0.04% 279
2024
Q3 		$353K Buy
+17,736
New +$329K 0.05% 340

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Cynosure Group's CPRX Position: Q4 2025 in Review

Cynosure Group sold out of Catalyst Pharmaceutical (CPRX) in Q4 2025, closing a stake of 18,777 shares — an estimated $370K sold.

Cynosure Group first reported a position in CPRX in Q3 2024 and held it in 5 quarters. The position peaked at $407K in Q2 2025. 373 funds tracked by Wall St. Rank hold CPRX as of Q4 2025.

  • Cynosure Group reported no remaining Catalyst Pharmaceutical position as of Q4 2025 after selling out during the quarter.
  • Cynosure Group sold 18,777 Catalyst Pharmaceutical shares in Q4 2025, an estimated $370K.
  • Cynosure Group first reported a position in Catalyst Pharmaceutical in Q3 2024 and held it in 5 quarters.
  • Cynosure Group's Catalyst Pharmaceutical position peaked at $407K in Q2 2025.
  • 373 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2025.

Based on Cynosure Group's 13F filing for Q4 2025, filed 17 Feb 2026.